Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 3

2(33.3%)

N/A

1(16.7%)

6Total

Phase 2(3)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06928376Phase 2Recruiting

A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

Role: collaborator

NCT06084819Phase 2Recruiting

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Role: collaborator

NCT06068621Phase 2Completed

Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia

Role: collaborator

NCT05524389Phase 3Not Yet Recruiting

Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions

Role: collaborator

NCT03955367Phase 3Unknown

Pelvic RT Versus Prophylactic Extended-field RT in Patients With Cervical Cancer

Role: collaborator

NCT02982668Not ApplicableTerminated

Optimizing Early Enteral Nutrition in Severe Stroke

Role: collaborator

All 6 trials loaded